Previous Close | 1.4000 |
Open | 1.4160 |
Bid | 1.4260 x 0 |
Ask | 1.5280 x 0 |
Day's Range | 1.4160 - 1.4160 |
52 Week Range | 0.6980 - 1.6120 |
Volume | |
Avg. Volume | 3 |
Market Cap | 50.069M |
Beta (5Y Monthly) | 0.58 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3200 |
Earnings Date | May 08, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Election of the board of directors and auditor
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted another US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the AmorphOX® drug delivery platform.
On March 13, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) announced that the Company intends to redeem early the Company's existing senior unsecured bonds with maturity in February 2025 (ISIN SE0015193958) (the "Existing Bonds").